Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers

Michael W. Graner, Yi - Zeng, Hanping Feng, Emmanuel Katsanis

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

With the clinical use of purified, tumor-derived chaperone proteins as anti-cancer vaccines already in clinical trial stages, we have focused our attention on the utility of chaperone-rich cell lysates (CRCL) in cancer immunotherapy. CRCL, as prepared from tumor lysates via a free solution-isoelectric focusing (FS-IEF) technique, is a high-yield vaccine enriched for numerous chaperone proteins. We have compared the efficacy of CRCL vaccines to that of individual chaperone protein vaccines in in vivo settings, including ELISPOT assays, tumor-growth assays and survival assays. In all experiments, CRCL vaccines were at least as effective, and in some settings perhaps even more effective, than either of the two most heavily studied components of CRCL, HSP70 and GRP94/gp96, in reduction in tumor growth and prolongation of survival in both prophylactic and pre-existing tumor settings against tumors of diverse origin and genetic background. Combining CRCL preparations with dendritic cells ex vivo resulted in a cellular vaccine that could eradicate pre-existing tumors in a high percentage of cases. The high yields of CRCL vaccines from small quantities of starting materials, the relative ease of its procurement and the functional data presented here suggest that CRCL vaccines are worthy of evaluation in pilot clinical trial cancer immunotherapy protocols.

Original languageEnglish (US)
Pages (from-to)226-234
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume52
Issue number4
StatePublished - Apr 1 2003

Fingerprint

Vaccines
Neoplasms
Therapeutics
Immunotherapy
Clinical Trials
Enzyme-Linked Immunospot Assay
Cancer Vaccines
Proteins
Isoelectric Focusing
Growth
Dendritic Cells

Keywords

  • Cancer immunotherapy
  • Chaperone-rich cell lysates
  • Dendritic cells
  • Heat shock/chaperone proteins

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. / Graner, Michael W.; Zeng, Yi -; Feng, Hanping; Katsanis, Emmanuel.

In: Cancer Immunology, Immunotherapy, Vol. 52, No. 4, 01.04.2003, p. 226-234.

Research output: Contribution to journalArticle

@article{788d3e845fc94cde86849b41811a7fd6,
title = "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers",
abstract = "With the clinical use of purified, tumor-derived chaperone proteins as anti-cancer vaccines already in clinical trial stages, we have focused our attention on the utility of chaperone-rich cell lysates (CRCL) in cancer immunotherapy. CRCL, as prepared from tumor lysates via a free solution-isoelectric focusing (FS-IEF) technique, is a high-yield vaccine enriched for numerous chaperone proteins. We have compared the efficacy of CRCL vaccines to that of individual chaperone protein vaccines in in vivo settings, including ELISPOT assays, tumor-growth assays and survival assays. In all experiments, CRCL vaccines were at least as effective, and in some settings perhaps even more effective, than either of the two most heavily studied components of CRCL, HSP70 and GRP94/gp96, in reduction in tumor growth and prolongation of survival in both prophylactic and pre-existing tumor settings against tumors of diverse origin and genetic background. Combining CRCL preparations with dendritic cells ex vivo resulted in a cellular vaccine that could eradicate pre-existing tumors in a high percentage of cases. The high yields of CRCL vaccines from small quantities of starting materials, the relative ease of its procurement and the functional data presented here suggest that CRCL vaccines are worthy of evaluation in pilot clinical trial cancer immunotherapy protocols.",
keywords = "Cancer immunotherapy, Chaperone-rich cell lysates, Dendritic cells, Heat shock/chaperone proteins",
author = "Graner, {Michael W.} and Zeng, {Yi -} and Hanping Feng and Emmanuel Katsanis",
year = "2003",
month = "4",
day = "1",
language = "English (US)",
volume = "52",
pages = "226--234",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "4",

}

TY - JOUR

T1 - Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers

AU - Graner, Michael W.

AU - Zeng, Yi -

AU - Feng, Hanping

AU - Katsanis, Emmanuel

PY - 2003/4/1

Y1 - 2003/4/1

N2 - With the clinical use of purified, tumor-derived chaperone proteins as anti-cancer vaccines already in clinical trial stages, we have focused our attention on the utility of chaperone-rich cell lysates (CRCL) in cancer immunotherapy. CRCL, as prepared from tumor lysates via a free solution-isoelectric focusing (FS-IEF) technique, is a high-yield vaccine enriched for numerous chaperone proteins. We have compared the efficacy of CRCL vaccines to that of individual chaperone protein vaccines in in vivo settings, including ELISPOT assays, tumor-growth assays and survival assays. In all experiments, CRCL vaccines were at least as effective, and in some settings perhaps even more effective, than either of the two most heavily studied components of CRCL, HSP70 and GRP94/gp96, in reduction in tumor growth and prolongation of survival in both prophylactic and pre-existing tumor settings against tumors of diverse origin and genetic background. Combining CRCL preparations with dendritic cells ex vivo resulted in a cellular vaccine that could eradicate pre-existing tumors in a high percentage of cases. The high yields of CRCL vaccines from small quantities of starting materials, the relative ease of its procurement and the functional data presented here suggest that CRCL vaccines are worthy of evaluation in pilot clinical trial cancer immunotherapy protocols.

AB - With the clinical use of purified, tumor-derived chaperone proteins as anti-cancer vaccines already in clinical trial stages, we have focused our attention on the utility of chaperone-rich cell lysates (CRCL) in cancer immunotherapy. CRCL, as prepared from tumor lysates via a free solution-isoelectric focusing (FS-IEF) technique, is a high-yield vaccine enriched for numerous chaperone proteins. We have compared the efficacy of CRCL vaccines to that of individual chaperone protein vaccines in in vivo settings, including ELISPOT assays, tumor-growth assays and survival assays. In all experiments, CRCL vaccines were at least as effective, and in some settings perhaps even more effective, than either of the two most heavily studied components of CRCL, HSP70 and GRP94/gp96, in reduction in tumor growth and prolongation of survival in both prophylactic and pre-existing tumor settings against tumors of diverse origin and genetic background. Combining CRCL preparations with dendritic cells ex vivo resulted in a cellular vaccine that could eradicate pre-existing tumors in a high percentage of cases. The high yields of CRCL vaccines from small quantities of starting materials, the relative ease of its procurement and the functional data presented here suggest that CRCL vaccines are worthy of evaluation in pilot clinical trial cancer immunotherapy protocols.

KW - Cancer immunotherapy

KW - Chaperone-rich cell lysates

KW - Dendritic cells

KW - Heat shock/chaperone proteins

UR - http://www.scopus.com/inward/record.url?scp=0038408927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038408927&partnerID=8YFLogxK

M3 - Article

C2 - 12669247

AN - SCOPUS:0038408927

VL - 52

SP - 226

EP - 234

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 4

ER -